HIV and HCV Intervention In Drug Treatment Settings - 1

January 11, 2017 updated by: University of Colorado, Denver

HIV and HCV Intervention in Drug Treatment Settings

The purpose of this study is to test two strategies to reduce the risk of contracting Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV) by reducing risk behaviors in patients undergoing drug detoxification.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

706

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Colorado
      • Denver, Colorado, United States, 80204 4507
        • Denver Health & Hosp Authority
      • Greeley, Colorado, United States, 80631
        • Island Grove RTC
    • Massachusetts
      • Fall River, Massachusetts, United States, 02720
        • SSTAR (Stanley St. Treatment & Resources, Inc)
    • Michigan
      • Kalamazoo, Michigan, United States, 49408
        • James Gilmore Jr. Treatment Center
    • Oregon
      • Eugene, Oregon, United States, 97402
        • Willamette Family Treatment Services
    • Rhode Island
      • North Kingstown, Rhode Island, United States, 02852
        • SSTAR of Rhode Island - North Kingstown
    • Washington
      • Kent, Washington, United States, 98032
        • Recovery Center King Co.-Kent Detox
      • Seattle, Washington, United States, 98144
        • Recovery Center King Co.-Seattle Detox

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Volunteers will be IV drug users already enrolled in drug detoxification treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
HIV/HCV injection risk behaviors

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Colorado, Denver

Collaborators

Oregon Health and Science University

Investigators

  • Principal Investigator: Robert Booth, Ph.D., University of Colorado, Denver

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2004

Primary Completion (Actual)

February 1, 2006

Study Completion (Actual)

February 1, 2006

Study Registration Dates

First Submitted

January 27, 2005

First Submitted That Met QC Criteria

January 27, 2005

First Posted (Estimate)

January 28, 2005

Study Record Updates

Last Update Posted (Estimate)

January 12, 2017

Last Update Submitted That Met QC Criteria

January 11, 2017

Last Verified

October 1, 2016

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • NIDA-CTN-0017-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Behavior Therapy

Clinical Trials on Behavior Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe